Department of Clinical and Molecular Medicine, Sapienza University, Rome, Italy.
Regional Referral Headache Centre, Sant'Andrea Hospital, Via di Grottarossa 1035, 00189, Rome, Italy.
BioDrugs. 2017 Dec;31(6):483-485. doi: 10.1007/s40259-017-0251-4.
Migraine is among the highest impact illnesses in the global population. Its negative ramifications are personal, social, economic and work related. Research on the development of new preventative migraine therapies has been idle for decades. The introduction, shortly, of an innovative pharmacological class useful for migraine prevention, namely monoclonal antibodies towards calcitonin gene-related peptide or its receptor, opens a new, immense therapeutic scenario. The necessity to manage the chronic and refractory forms of migraine must not take our attention away from the target of the pre-chronic forms. This is the most important target in every study. Indeed, by reducing the evolution towards chronic and consequently refractory chronic migraine, we will reduce complications caused by pharmacological abuse, the serious disability of these devastating chronic states, and the healthcare expenses needed to manage chronicity, abuse and consequent pathologies. We will, lastly, be able to rehabilitate these patients to achieve a quality working and social life, and facilitate their reintegration into daily normality.
偏头痛是全球人群中影响最大的疾病之一。它的负面影响包括个人、社会、经济和与工作相关的方面。几十年来，预防偏头痛新疗法的研究一直处于停滞状态。不久，一种用于偏头痛预防的创新药物类别——降钙素基因相关肽或其受体的单克隆抗体的引入，开辟了一个全新的、广阔的治疗前景。管理慢性和难治性偏头痛的必要性不应使我们忽视慢性前形式的目标。这是每个研究中最重要的目标。事实上，通过减少向慢性和随之而来的难治性慢性偏头痛的发展，我们将减少药物滥用引起的并发症、这些破坏性慢性状态的严重残疾以及管理慢性、滥用和随之而来的病理所需的医疗保健费用。最后，我们将能够使这些患者康复，以实现高质量的工作和社交生活，并促进他们重新融入日常生活。
